Understanding the determinants for site-specific ubiquitination by E3 ligase components of the ubiquitin machinery is proving to be a challenge. In the present study we investigate the role of an E3 ligase docking site (Mf2 domain) in an intrinsically disordered domain of IRF-1 [IFN (interferon) regulatory factor-1], a shortlived IFNγ -regulated transcription factor, in ubiquitination of the protein. Ubiquitin modification of full-length IRF-1 by E3 ligases such as CHIP [C-terminus of the Hsc (heat-shock cognate) 70-interacting protein] and MDM2 (murine double minute 2), which dock to the Mf2 domain, was specific for lysine residues found predominantly in loop structures that extend from the DNA-binding domain, whereas no modification was detected in the more conformationally flexible C-terminal half of the protein. The E3 docking site was not available when IRF-1 was in its DNA-bound conformation and cognate DNA-binding sequences strongly suppressed ubiquitination, highlighting a strict relationship between ligase binding and site-specific modification at residues in the DNA-binding domain. Hyperubiquitination of a non-DNA-binding mutant supports a mechanism where an active DNA-bound pool of IRF-1 is protected from polyubiquitination and degradation.
INTRODUCTION
Protein ubiquitination was first described as part of the proteasomal degradation pathway and has since been shown to play a major role in regulating a wide range of cellular pathways. Cell-cycle progression, DNA damage and repair, and transcription are all subject to fine control by the ubiquitin pathway. The ubiquitin transfer cascade comprises three enzymes, E1, E2 and E3. In the initial step, ubiquitin is activated by the E1 (ubiquitin-activating enzyme) and subsequently transferred to the E2 (ubiquitin-conjugating enzyme) which forms a complex with the E3 (ubiquitin ligase) and the substrate [1] . The main class of E3 ligases [RING including PHD (plant homeodomain) and U-box domain proteins] act by facilitating the transfer of ubiquitin from the E2 to one, or several, lysine residues in the substrate. The outcome of ubiquitination depends on the type of modification (mono-compared with poly-), the configuration of the chain linkages and the position of the modified residue in the primary amino acid sequence of the protein. The E3 is believed to determine substrate specificity and interplay between the E3 and E2 results in different chain linkages [2] . Ubiquitin contains seven lysine residues (Lys 6 , Lys 11 , Lys 27 , Lys 29 , Lys 33 , Lys 48 and Lys 63 ); any one of these lysine residues, in addition to the N-terminal methionine residue, can be connected to another ubiquitin molecule resulting in the formation of di-or poly-ubiquitin chains with a variety of different linkages [2, 3] . Additionally, ubiquitin chains with mixed linkages and branches have been observed, adding to the overall complexity of the system [4] . While Lys 48 chains are associated with protein degradation, Lys 63 has roles in processes such as the response to stress, membrane trafficking and endocytosis. Lys 11 signals proteasomal degradation and can alter subcellular localization, cell division and protein activity [5] . Although progress is being made on understanding the cellular roles of linkage-specific ubiquitination, the mechanisms involved in ubiquitin transfer, and particularly the selection of specific ubiquitin-acceptor residues, remain elusive.
In contrast with phosphorylation, where specific peptide motifs are known to serve as phosphorylation signals for different kinases, no such definite sequence motifs have been identified for E3 ligases and prediction of lysine residues that are subject to modification remains difficult [6] . IRF-1 [IFN (interferon) regulatory factor-1] is an IFN-regulated transcription factor and a key effector of IFNγ -activated changes in gene expression. IRF-1 has a strong link to human health with loss of function leading to the development of some cancers [7, 8] , whereas its overexpression is associated with chronic autoimmune diseases [9] [10] [11] [12] . Like many other transcription factors, IRF-1 is turned over very rapidly, with a half-life of approximately 20-30 min in cultured cells, and it is degraded via the ubiquitinproteasome pathway [13, 14] . We formerly reported that CHIP [Cterminus of the Hsc (heat-shock cognate) 70-interacting protein] binds to a central intrinsically disordered domain (Mf2 domain) of IRF-1 and mediates its ubiquitination under certain stress conditions [15] . This led us to ask (i) whether ligase docking plays a role in selecting lysine residues for modification, and (ii) what would be the outcome if the E3 could no longer dock to the Mf2 domain. We report in the present paper that IRF-1 ubiquitination by CHIP is proximal to its binding site and that only selected lysine residues in the structured DBD (DNA-binding domain) of IRF-1 were able to act as ubiquitin-acceptor sites. We characterize MDM2 (murine double minute 2) as a second Mf2-domain-binding ligase and show that it also mediates DBD ubiquitination. In addition, we show that IRF-1 is only available for E3 docking and ubiquitination when in a DNA-unbound state, leading us to propose a mechanism by which IRF-1 degradation is partly controlled by its ability to bind DNA.
MATERIALS AND METHODS
Cell culture, transfection, FLAG pull-down, half-life and immunoblotting HCT-116 cells were maintained in McCoy's medium (Invitrogen). Medium was supplemented with 5 % (v/v) FBS (fetal bovine serum; Biosera) and 1 % (v/v) penicillin/streptomycin (Invitrogen), and cells were grown at 37
• C with 5 % CO 2 . At 80 % confluence, cells were transfected using Attractene (Invitrogen) following the manufacturer's instructions. FLAG pull-down and half-life determination was carried out as described previously [13, 16] . Immunoblotting was performed as described previously [17] .
Reagents, plasmids and protein preparation
The antibodies used were anti-IRF-1 mAb (monoclonal antibody) (BD Biosciences) and anti-IRF-1 C20 pAb (polyclonal antibody) (Santa Cruz Biotechnology), DO1 mAb (anti-p53; Moravian Biotechnology), anti-FLAG M2 mAb (Sigma), 4B2 mAb (anti-MDM2) and anti-CHIP 3.1 (a gift from Dr Borek Vojtesek, Masaryk Memorial Cancer Institute, Brno, Czech Republic). Secondary antibodies were purchased from Dako. Antibodies were used at the concentrations indicated by the supplier and at 1 μg/ml for DO1 and anti-CHIP. pDEST15-IRF-1 [GST (glutathione transferase)-IRF-1] mutants were constructed using a QuikChange ® site-directed mutagenesis kit (Stratagene) with primers designed for a codon change from tryptophan to arginine or lysine to arginine (Sigma). GST-IRF-1 and GST-MDM2 were purified using glutathione-Sepharose (GE Healthcare) following the manufacturer's instructions. The GST tag was cleaved off MDM2 using Prescission Protease (GE Healthcare) following the manufacturer's instructions. His-CHIP, His-UbcH5 and His-SET (pET-26b-SET was from J. Libermann and T. Tuschi via Addgene [18] ) were purified using Ni-NTA (Ni 2 + -nitrilotriacetate) agarose (Qiagen) following the manufacturer's instructions. Kap-1 was purified as described previously [16] (pGEX-4T1-Kap-1 was a gift from Dr A. Ivanov, West Virginia University, Morgantown, West Virginia, U.S.A. [19] ). Untagged p53 purified from insect cells was a gift from Dr Jennifer Fraser and Professor Ted Hupp (both from the University of Edinburgh, Edinburgh, Scotland, U.K.).
Ubiquitination assay
In vitro ubiquitination assays were performed as described previously [20] using 25 ng of substrate [GST-IRF-1 WT , GST-IRF-1 W11R or p53 as indicated; WT is wild-type] and His-CHIP or MDM2 as indicated. Reactions were incubated at 30
• C for 15 min unless otherwise indicated. The reactions were terminated by the addition of SDS sample buffer and analysed on a 4-12 % NuPAGE gel in a Mops buffer system (Invitrogen) followed by immunoblotting.
In vivo ubiquitination assays were carried out as described previously [20] . Briefly, HCT-116 cells were transfected with the indicated amounts of His-ubiquitin, IRF-1 and MDM2 or CHIP and treated with 50 μM MG-132 for 4 h. Cells were harvested and 20 % was lysed directly in 0.1 % NP40 (Nonidet P40) lysis buffer [25 mM Hepes (pH 7.5), 0.1 % NP40, 150 mM KCl, 5 mM DTT (dithiothreitol), 50 mM NaF and protease inhibitor mix] and separated by PAGE (12 % gel) followed by immunoblot analysis; for the remaining cells, His-ubiquitin conjugates were isolated using Ni-NTA agarose as described previously [20] .
EMSA (electrophoretic mobility-shift assay) and ELISA
EMSAs were carried out as described previously [21] . Briefly, 100-300 ng of GST-IRF-1 WT or GST-IRF-1 W11R was incubated with either 40 ng of 32 P-labelled C1 probe [21] , the ISRE (IFN-stimulated response element) sequences from the promoter sequences of caspase 8 [22] , ISG-15 [23] , ISG-20 [24] , TRAIL [TNF (tumour-necrosis-factor)-related apoptosisinducing ligand] [25] or an oligonucleotide from the p53-binding site on the 21 promoter [26] in EMSA buffer [20 mM Hepes (pH 7.5), 50 mM KCl, 5 % glycerol, 0.4 mM DTT, 0.1 mg/ml BSA, 0.5 % Triton X-100, 0.125 mg/ml poly(dIdC) and 0.04 mg/ml salmon sperm DNA] for 30 min at room temperature (24 • C). After the addition of 6× loading buffer samples were analysed by PAGE (5 % gel) and radiolabelled bands were detected using a Storm840 phosphoimager (GE Healthcare).
Protein-binding assays (ELISAs) detecting protein-protein or protein-peptide binding were carried out as described previously [15] .
MS analysis
Samples were analysed by 4-12 % gradient SDS/PAGE. The gel track was excised and divided into approximately 15 sections. Each section was cut into 1 mm cubes. These were then subjected to in-gel digestion using trypsin; samples were loaded on to a C18 column in 0.05 % TFA (trifluoroacetic). Peptides were eluted using acetonitrile in formic acid (2 % acetonitrile in 0.01 % formic acid to 90 % acetonitrile in 0.08 % formic acid). The eluate was sprayed on to an Ultimate 3000 nLC (Dionex) column coupled to a LTQ Orbitrap XL (Thermo Scientific) and the Top 5 Method was used: FT (Fourier transform)-MS plus five IT (ion trap)-MS/MS (tandem MS) (95 min acquisition). Orbitrap XL RAW data files were extracted with Raw2MSM (Version 1.7.2007.04.11) to generate a Mascot generic file (.msm). Extracted data was searched against the IPI (International Protein Index) human database (date 20100502) using the Mascot search engine (version 2.2). The following parameters were used: type of search, MS/MS ion search; enzyme, trypsin/P; fixed modifications, carbamidomethyl (C); variable modifications, acetyl (N-term), dioxidation (M), Gln→pyro-Glu (N-term Q), GlyGly (K), GlyGly (N-term), oxidation (M); mass values, monoisotopic; protein mass, unrestricted; peptide mass tolerance, + − 10 p.p.m. (# 13 C = 2); fragment mass tolerance, + − 0.6 Da; and maximum missed cleavages, two. Hits with a Mascot score under ten were discarded. Two separate analyses, using different batches of CHIP-ubiquitinated IRF-1, were carried out in the proteomics facility in the College of Life Sciences, University of Dundee, Dundee, U.K.
Generation of models using HADDOCK
The 'Easy Interface' of the HADDOCK web server [27, 28] was used to generate models of the IRF-1 DBD conjugated to ubiquitin. The C-terminal glycine residue of ubiquitin (Gly 76 ) was selected as the active residue on ubiquitin (structure obtained from PDB code 1UBQ, chain A [29] ) and either Lys 39 were selected. The best four structures in the three clusters with the best HADDOCK score were analysed.
RESULTS

MDM2 can act as an E3 ligase for IRF-1 in vitro and in cells
CHIP, a U-box E3 ligase, docks to a multi-protein-binding interface in the intrinsically disordered Mf2 domain of IRF-1 and this interaction is required for efficient modification of IRF-1 by CHIP in cells [16] . Interestingly, a domain with homology with the Mf2 is involved in ubiquitination of IRF-2 ( Figure 1A ), a close relative of IRF-1, by the RING E3 ligase MDM2 [30] , suggesting that the Mf2 may comprise a general docking site for IRF-1 and IRF-2 E3 ligases. Thus, in order to acquire additional E3 ligase tools to study the role of the Mf2 in ubiquitination, we determined whether MDM2 could act as a docking-dependent ligase for IRF-1.
We first overexpressed FLAG-IRF-1 in HCT-116 cells and asked whether MDM2 was detectable after isolation of IRF-1 complexes using a FLAG pull-down, and whether loss of the Mf2 domain affected binding. The results show that WT IRF-1 forms a complex containing MDM2 in cells ( Figure 1B , lanes 2 and 5), whereas an IRF-1 Mf2 mutant ( 106-140) is not associated with MDM2 (lanes 3 and 6). To establish whether MDM2 could bind directly to IRF-1 or whether other cellular factors were required for complex formation, protein interaction assays were carried out using purified components. GST-IRF-1 was immobilized on a microtitre plate and incubated with a titration of MDM2 in the mobile phase. Results of this assay showed that MDM2 bound to IRF-1 in a dose-dependent manner ( Figure 1C ). To identify the binding interface between MDM2 and IRF-1, a peptide-protein interaction assay was used. An overlapping IRF-1 peptide library (Supplementary Figure  S1 at http://www.biochemj.org/bj/449/bj4490707add.htm) was immobilized and incubated with a constant amount of MDM2 in the mobile phase; binding was then detected using an anti-MDM2 antibody. MDM2 bound to an IRF-1 peptide from within the Mf2 domain (peptide 8, VRVYRMLPPLTKNQRKERKS; Figure 1D ) with homology with the MDM2-binding site-I of IRF-2 ( Figure 1A) .
Whether formation of MDM2-IRF-1-containing complexes was sufficient to signal IRF-1 ubiquitination was determined using in vitro and cell-based approaches. Using a minimal ubiquitination assay employing only purified components, we established that IRF-1 could act as a substrate for MDM2 and that there was a positive correlation between the efficiency of IRF-1 ubiquitination and the concentration of MDM2 added to the assay ( Figure 1E ). In-cell ubiquitination assays using His-ubiquitin, IRF-1 and MDM2 ( Figure 1F ) were assembled in HCT-116 cells. After isolation and analysis of His-ubiquitinated proteins, an increase in the amount of ubiquitinated IRF-1 was seen in the presence of MDM2 ( Figure 1F ; compare lane 7 with lane 8). It should be noted that ubiquitination of IRF-1 seen in lane 7 ( Figure 1F ) is mediated by endogenous E3-ligase activity. To determine whether ubiquitination of IRF-1 by MDM2 had an effect on its half-life, HCT-116 cells were transfected with MDM2 and treated with the protein synthesis inhibitor cycloheximide. The loss of IRF-1 protein was then monitored over time by immunoblot analysis ( Figure 1G ). The results show that MDM2 overexpression did not lead to a decrease in the half-life of IRF-1, rather it gave a slight, but reproducible, increase in its half-life. This is in agreement with the idea that MDM2 is a monoubiquitin ligase that can only polyubiquitinate its substrates under specific conditions or in the presence of an E4 ligase [31] ; it also suggests that MDM2 may be involved in the regulation of IRF-1 activity rather than its rate of degradation.
Mf2 docking directs DBD ubiquitination by CHIP and MDM2
In order to investigate whether binding of E3 ligases to the Mf2 domain facilitates ubiquitination at specific lysine residues, IRF-1 ubiquitin-acceptor sites modified in the presence of either CHIP or MDM2 were determined using MS. First, optimal conditions for IRF-1 ubiquitination were established by performing a time course of ubiquitination in vitro over 30 min with either CHIP (Figure 2A , left-hand panel) or MDM2 (right-hand panel). For identification of ubiquitination sites by MS, IRF-1 was ubiquitinated for either 10 or 45 min and discrete ubiquitinated intermediates were excised and subjected to in-gel digestion using trypsin ( Figure 2B ). Ubiquitin-modified residues are protected from trypsin cleavage, resulting in a distinct cleavage pattern for the ubiquitinated protein. Furthermore, ubiquitin that is attached to the protein is cleaved off at a C-terminal arginine residue leaving a di-glycine peptide remnant that adds 114.043 Da to the ubiquitinated peptide. The modified cleavage pattern, together with the mass additions, facilitate identification, by MS, of peptides that have been ubiquitinated ( Figure 2B) .
Although there are a total of 23 lysine residues in the primary amino acid sequence of IRF-1, only a subset of those were detected by MS as being ubiquitin-acceptor sites for the Mf2-binding ligases CHIP or MDM2 (Figures 2C and 2D) . Strikingly, IRF-1 was predominantly ubiquitinated in, or adjacent to, the DBD and no modified residues from within the C-terminal half of the protein were detected with either of the E3 ligases. Although both MDM2 and CHIP modified Lys 39 , Lys 50 and Lys 117 , in the two independent analyses of CHIP-ubiquitinated IRF-1 Lys 95 modification was not detected, whereas this residue was modified when MDM2 provided the E3 activity. Similarly, Lys 78 was detected only in the CHIP-ubiquitinated samples. Although this difference in specificity remains to be confirmed using a second analytical technique, the existing data suggest that although Mf2-directed ubiquitination of IRF-1 is specific for the DBD, there could be subtle differences in the exact residues targeted by MDM2 and CHIP. Using the HADDOCK web server [27, 28] , a model of the ubiquitinated IRF-1 DBD was generated with ubiquitin docked to the ubiquitin-acceptor sites identified (only sites present in the crystal structure [32] , amino acids 7-111 are shown; Figure 2E and Supplementary Figure S2 at http://www.biochemj.org/bj/449/bj4490707add.htm). Interestingly, modelling suggests that modification at three of the five ubiquitination sites identified (Lys 39 , Lys 50 and Lys 78 ) would result in ubiquitin occupying an overlapping three-dimensional space. Thus ubiquitination at any one of these three sites could potentially block ubiquitination at the other two sites. In order to investigate this model experimentally in vitro ubiquitination assays, using either WT ubiquitin or an ubiquitin mutant in which all of the lysine residues were mutated to arginine (NoK ubiquitin), were used. For the majority of E3 ligases NoK ubiquitin can only result in the formation of monoubiquitinated residues as chain elongation is not possible (linear ubiquitin chain formation by SHARPIN [33] is an exception to this). We found that the ubiquitin mutant was, in general, a poor substrate for in vitro ubiquitination with slower conversion of IRF-1 into its monoubiquitinated form than is seen in the presence of WT ubiquitin. However, when assay conditions were adapted to facilitate ubiquitination we saw that monoubiquitination provided a maximum of three ubiquitins added per IRF-1 molecule, and in the case of MDM2 a single ubiquitinated form was predominant ( Figure 3E , bottom panel; compare lanes 3 and 5 with lanes 2 and 4), suggesting that a maximum of three out of the five ubiquitin-acceptor sites identified can be modified at any one time.
If the modelling is correct we would predict that mutation of Lys 39 , Lys 50 and Lys 78 individually would not be sufficient to affect IRF-1 DBD monoubiquitination. Therefore to complement the above approach a series of IRF-1 point mutant proteins was generated in which Lys 39 , Lys 50 and Lys 78 were individually mutated to arginine. When the mutant proteins were used as substrates for CHIP in the presence of NoK ubiquitin, loss of Lys 39 and Lys 78 did not produce qualitative or quantitative changes in monoubiquitination of IRF-1, consistent with the idea that ubiquitination at either one of these residues produces a similar outcome and that ubiquitination at these two sites is mutually exclusive. Although mutation of Lys 50 did have an effect on monoubiquitination, with loss of the slowest migrating ubiquitinated form of IRF-1, this mutant was susceptible to cleavage during expression and the cleavage product was also a substrate for CHIP, making the data difficult to interpret. Unfortunately, we were not able to test the modelling data using double and triple mutants as the introduction of multiple lysine point mutations produced proteins that were extremely susceptible to cleavage during expression.
Taken as a whole, the data in this section support the modelling data and suggest that ubiquitination of Lys 39 and Lys 78 , and potentially Lys 50 , are mutually exclusive and might therefore result in the generation of a very similar 'molecular signature'.
DNA-bound IRF-1 is protected from ubiquitination in vitro
When the ubiquitin-modified residues were mapped on to the available IRF-1 DBD crystal structure, we found that Lys 39 , Lys 50 and Lys 95 were located in exposed loops (L1, L2 and L3), whereas Lys 78 was positioned within the α3-helix which forms the second helix of the HTH (helix-turn-helix) homologous motif ( Figure 3A) . As the ubiquitin-acceptor sites are all located within the DBD, with Lys 78 and Lys 95 being at the DNA-binding interface ( Figure 3A) , we reasoned that modification may be affected by the sequence-specific DNA-binding activity of IRF-1.
To test this, IRF-1 was pre-incubated with a consensus site DNA oligonucleotide (C1), which we show can bind to GST-IRF-1 WT ( Figure 3B, lanes 3-5) , but not a DNA-binding mutant, IRF-1 W11R (lanes 6-9), in an EMSA and is supershifted by an anti-IRF-1 mAb. A control oligonucleotide that does not interact with IRF-1 (p21c) was used as a negative control ( Figure 3B , lanes 7-10). Whereas control DNA (p21c) had no significant effect on the ubiquitination of IRF-1 by CHIP ( Figure 3C , left-hand panel) or MDM2 (right-hand panel), addition of IRF-1 consensus site DNA (C1) almost completely suppressed ubiquitination. To control for non-specific effects of DNA on IRF-1 we used a non-DNAbinding mutant (IRF-1 W11R ; Figure 3B ) and asked whether this was refractive to the effects of DNA. Figure 3(C) shows that whereas C1 oligonucleotides inhibit the ubiquitination of wild-type IRF-1 (lanes 4 and 5) they had no significant effect on the ubiquitination of IRF-1 W11R (lanes 9 and 10). As an additional control we showed that C1 DNA did not affect CHIP activity directly as there was no effect on the ability of CHIP to mediate autoubiquitination ( Figure 3C, bottom panel) . Ubiquitination of p53, a second wellcharacterized substrate for both CHIP ( Figure 3D , left-hand panel) and MDM2 ( Figure 3D , right-hand panel), was not affected by p53 binding to DNA from the p21 promoter (p21c DNA), suggesting that protection of IRF-1 from ubiquitination by DNA is not a property of all transcription factors ( Figure 3D ).
To expand on the observation described above, which used an optimized IRF-1 consensus DNA oligonucleotide, a range of oligonucleotide probes based on naturally occurring binding elements from IRF-1 target gene promoters was examined. Elements from all of the IRF-1 target genes tested were able to inhibit CHIP-and MDM2-mediated ubiquitination and there was good agreement between the ability of IRF-1 to bind DNA in an EMSA ( Figure 3E , bottom panel) and the ability of the oligonucleotide to inhibit ubiquitination of IRF-1 in an in vitro ubiquitination assay ( Figure 3E , top panels). For example, IRF-1 binds only weakly to an oligonucleotide based on the TRAIL promoter and this probe is a weak inhibitor of IRF-1 ubiquitination ( Figure 3E , bottom panel, lane 5).
IRF-1 bound to DNA is unable to associate with proteins that interact with its Mf2 domain
We reasoned that there were two possible mechanisms to explain the loss of IRF-1 ubiquitination when in its DNA-bound form; first the targeted lysine residues may be 'cryptic' and therefore inaccessible to the ligases, or secondly, the ability of IRF-1 to bind to CHIP or to MDM2 may be impaired. As the available structural data for the DBD of IRF-1 bound to its cognate DNA element [32] suggests that at least some of the required lysine residues are still available for ubiquitination ( Figure 3A ; for example Lys 50 ), we concentrated on the second option, i.e. a change in the affinity of IRF-1 for Mf2-binding proteins. To address the effects of IRF-1 DNA binding on its ability to interact with components of the ubiquitination system, we used protein-interaction assays to measure CHIP binding to IRF-1 protein that had been preincubated with either C1 oligonucleotide or control DNA (p21c). Initial titrations demonstrated binding of native unliganded IRF-1 in solution to immobilized CHIP in a dose-dependent manner ( Figure 4A, left-hand panel) . On the basis of this assay a fixed amount of CHIP was immobilized and incubated with a constant amount of IRF-1 that had been pre-incubated with a titration of either C1 or p21c. Figure 4(A) (right-hand panel) shows that whereas IRF-1 binding to CHIP was largely unaffected by p21c, titration of C1 into the assay inhibited CHIP binding. The results of this assay suggest that stable binding of CHIP to IRF-1 is severely restricted when IRF-1 is in its DNA-bound form.
Similarly, when we tested binding of MDM2 to IRF-1 in its DNA-bound and -unbound form, MDM2 bound preferentially to the unbound form of IRF-1 ( Figure 4B ). To test whether CHIP and MDM2 binding had a reciprocal effect on DNA binding we examined whether the ligases could compete with DNA for binding to IRF-1 using an EMSA ( Figure 4C ). Neither CHIP nor MDM2 had any effect on the ability of IRF-1 to bind to DNA, suggesting that IRF-1 has a higher affinity for DNA than for the Mf2-binding protein. As we have shown that the Mf2 domain is a multi-protein-binding site that interacts with a number of other IRF-1 regulators, we also tested the effect of DNA binding on the interaction of IRF-1 with Kap-1 and SET [16] . Figure 4(D) shows reduced binding of IRF-1 to both Kap-1 and SET when in its DNA-bound state.
The crystal structure of the IRF-1 DBD in complex with its cognate promoter-binding element suggests that residues from within the Mf2 domain are not required for DNA binding [30] , thus the results of the present study can be interpreted to suggest that access to the Mf2 interface is controlled through changes in the conformation of IRF-1 rather than through direct competition for binding to DNA. However, as deletion of the Mf2 domain prevents IRF-1 from binding to DNA (Supplementary Figure S3 at http://www.biochemj.org/bj/449/bj4490707add.htm) we cannot completely rule out the possibility that residues from the Mf2 contribute to binding through a direct contact with the DNA.
In summary the experiments presented here suggest that Mf2-domain-binding partners are likely to function only on the unliganded form of the protein. Furthermore, the observation that neither MDM2 nor CHIP is able to ubiquitinate IRF-1 unless they are bound to the protein lends strong support for a direct relationship between E3-ligase binding, ubiquitination and sitespecificity.
Ubiquitination of IRF-1 in cells is enhanced in a DNA-binding mutant
Taken together, the above observations led us to hypothesize that IRF-1 is 'protected' from ubiquitination, and therefore presumably from degradation, when it is in its transcriptionally active DNA-bound conformation. To lend support to this hypothesis, we determined whether a non-DNA-binding mutant of IRF-1 was more or less prone to ubiquitination than the wildtype protein. We first confirmed that specific DNA does not inhibit binding of CHIP to IRF-1 W11R in vitro using a proteinprotein interaction assay. CHIP was coated on to a microtitre plate and incubated with IRF-1 and a titration of C1 DNA ( Figure 5A together with His-ubiquitin we found that the IRF-1 W11R mutant was hyperubiquitinated when compared with the WT protein ( Figure 5C, compare lanes 3 and 4) , supporting the idea that IRF-1 which is not associated with the chromatin is more 'available' for ubiquitination by endogenous Mf2-domain-interacting ligases. Thus although CHIP ubiquitinates IRF-1 WT and IRF-1 W11R to a similar extent in vitro, in cells the Trp 11 mutant is preferentially ubiquitinated, supporting the concept that free IRF-1 may be turned over more rapidly than the pool of IRF-1 that is bound, or able to bind, to DNA.
DISCUSSION
In recent years, ubiquitination has been linked to a growing number of cellular processes and it is now apparent that ubiquitin modification is involved not only in proteasomal degradation, but serves as a common mechanism for executing a wide variety of signalling events [1, 2] . This raises the question of how the ubiquitin reaction is controlled at multiple levels in order to generate distinct outcomes. Differences in the result of ubiquitination can be achieved by the position of the target lysine residue in the acceptor protein [34] , as well as by the use of different linkages and length of the ubiquitin chain. Yet, our understanding of ubiquitin-acceptor site selection lags behind a growing structural and mechanistic understanding of chain elongation and linkage determination [2] . One of the mechanisms proposed for ubiquitin-acceptor site specificity is that the E3 positions the charged E2 in close proximity to the target lysine residue and thereby determines which residues are subject to modification [35] . Thus while artificial 'tethering' of some E2s to their targets in the absence of an E3 is sufficient to signal substrate ubiquitination, this process is fairly nondiscriminatory leading to promiscuous modification of lysine residues. In the presence of the E3, however, only a subset of the lysine modified by the E2 alone are ubiquitinated [36] , suggesting that, as well as stimulating discharge of the ubiquitin from the E2 through allosteric mechanisms [37, 38] , E3 ligases may also act to restrain the E2, ensuring that only specific target residues are modified. Analysis of the UbcH5c-ubiquitin complex by both NMR and SAXS (small-angle X-ray scattering) [39] has shown that the conjugate is very flexible and can exhibit a range of conformations in solution, explaining how one E3 ligase can mediate ubiquitination of several different residues within a target protein. The results of the present study are in good agreement with this mechanism; we propose that IRF-1 ubiquitination is specific to its DBD and that this is achieved through docking of E3 ligases to its Mf2 domain followed by ubiquitination of the lysine residues in close proximity. However, we also note that other DBD lysine residues as well as lysine residues in the Mf2 domain itself are not ubiquitinated by either MDM2 or CHIP, suggesting that ubiquitination of these residues is sterically unfavourable.
The observation that DNA binding protects IRF-1 from ubiquitination is intriguing as it suggests a mechanism by which turnover of this transcription factor might decrease when it is in an active state, i.e. when part of a pre-initiation complex. In recent years it has become clear that the ubiquitin-proteasome system and the transcriptional machinery are intimately linked, and that ubiquitin-mediated proteolysis can enhance the activity of TAs (transcriptional activators). This is known as the 'activation by destruction' mechanism [40] and was first indicated by the observation that the transactivation domain and the region required for degradation (degron) overlap in many TAs, including IRF-1 [41] . Furthermore, factors that affect the rate of turnover for this group of transcription factors typically also affect their transactivation potential [40, 42] . In keeping with this we have developed nanobodies to a negative regulatory domain of IRF-1 and, in addition to activating the TA activity of endogenous IRF-1 by up to 8-fold, they also modulate the rate of IRF-1 degradation [40] . The most popular hypothesis to explain the connection between degradation and TA function in gene expression is based on a 'suicide' model where activator degradation is somehow required as part of the activation mechanism and potentially also to terminate the signal [42] . Implicit in this model is that the TA is not subject to degradation prior to completing its function or when part of an active DNA-bound complex [42] . In the present study we show that DNAbound IRF-1 has a cryptic or inaccessible E3-binding site, and that a non-DNA binding mutant of IRF-1 is hyperubiquitinated in comparison with the WT protein ( Figure 6 ). These data support the idea that IRF-1 is 'protected' from degradation when it is part of an active pre-initiation complex, but can be rapidly degraded when it is not functional or when it has completed its function. How the 'suicide' model fits in with recent findings that TAs take part in 'tread-milling' rapidly on and off the chromatin [43] has not been explained. It will therefore be of interest to further dissect the role of polyubiquitination and its interplay with other forms of post-translational modification in the regulation of IRF-1 activity as a transcription factor.
In conclusion, in the present paper we report that ubiquitination of residues in the DBD of IRF-1 is achieved through E3-ligase binding to an adjacent multi-protein docking site resulting in the selective modification of several lysine residues. Docking of the E3 to its substrate is therefore not only required for ubiquitination, but also determines the specificity of the reaction. If the E3 cannot bind to its substrate, for example when IRF-1 is bound to DNA, it is not able to mediate DBD ubiquitination, suggesting a mechanism by which an active pool of IRF-1 might be protected from degradation in cells.
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